State Street’s Insight Molecular Diagnostics IMDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $166K | Buy |
50,754
+3,000
| +6% | +$17.4K | ﹤0.01% | 3936 |
|
|
2025
Q4 | $358K | Buy |
47,754
+5,900
| +14% | +$33.3K | ﹤0.01% | 3768 |
|
|
2025
Q3 | $139K | Buy |
41,854
+22,300
| +114% | +$62.9K | ﹤0.01% | 3989 |
|
|
2025
Q2 | $59.1K | Hold |
19,554
| – | – | ﹤0.01% | 4070 |
|
|
2025
Q1 | $59.8K | Hold |
19,554
| – | – | ﹤0.01% | 4066 |
|
|
2024
Q4 | $46.5K | Hold |
19,554
| – | – | ﹤0.01% | 4115 |
|
|
2024
Q3 | $55.7K | Hold |
19,554
| – | – | ﹤0.01% | 4081 |
|
|
2024
Q2 | $57.7K | Buy |
19,554
+3,265
| +20% | +$8.97K | ﹤0.01% | 4115 |
|
|
2024
Q1 | $47.7K | Hold |
16,289
| – | – | ﹤0.01% | 4172 |
|
|
2023
Q4 | $40.4K | Hold |
16,289
| – | – | ﹤0.01% | 4232 |
|
|
2023
Q3 | $53.4K | Buy |
16,289
+2,197
| +16% | +$8.18K | ﹤0.01% | 4273 |
|
|
2023
Q2 | $64.8K | Hold |
14,092
| – | – | ﹤0.01% | 4347 |
|
|
2023
Q1 | $99.9K | Hold |
14,092
| – | – | ﹤0.01% | 4331 |
|
|
2022
Q4 | $90.4K | Hold |
14,092
| – | – | ﹤0.01% | 4396 |
|
|
2022
Q3 | $206K | Sell |
14,092
-2,265
| -14% | -$39.2K | ﹤0.01% | 4129 |
|
|
2022
Q2 | $294K | Sell |
16,357
-51,519
| -76% | -$1.17M | ﹤0.01% | 4038 |
|
|
2022
Q1 | $2.02M | Sell |
67,876
-1,397
| -2% | -$44.7K | ﹤0.01% | 3558 |
|
|
2021
Q4 | $3.01M | Sell |
69,273
-905
| -1% | -$52.1K | ﹤0.01% | 3490 |
|
|
2021
Q3 | $5M | Buy |
70,178
+7,018
| +11% | +$645K | ﹤0.01% | 3241 |
|
|
2021
Q2 | $7.25M | Buy |
63,160
+7,692
| +14% | +$751K | ﹤0.01% | 3065 |
|
|
2021
Q1 | $5.76M | Buy |
55,468
+8,844
| +19% | +$840K | ﹤0.01% | 2990 |
|
|
2020
Q4 | $2.23M | Buy |
46,624
+12,392
| +36% | +$455K | ﹤0.01% | 3319 |
|
|
2020
Q3 | $952K | Buy |
34,232
+2,999
| +10% | +$86K | ﹤0.01% | 3452 |
|
|
2020
Q2 | $1.19M | Buy |
31,233
+9,790
| +46% | +$506K | ﹤0.01% | 3370 |
|
|
2020
Q1 | $1.05M | Sell |
21,443
-317
| -1% | -$15.5K | ﹤0.01% | 3293 |
|
|
2019
Q4 | $979K | Buy |
21,760
+718
| +3% | +$25.9K | ﹤0.01% | 3416 |
|
|
2019
Q3 | $884K | Buy |
21,042
+3,426
| +19% | +$135K | ﹤0.01% | 3424 |
|
|
2019
Q2 | $877K | Buy |
+17,616
| New | +$1.46M | ﹤0.01% | 3439 |
|
|
2018
Q2 | – | Sell |
-911
| Closed | -$39K | – | 3786 |
|
|
2018
Q1 | $39K | Buy |
911
+116
| +15% | +$7.67K | ﹤0.01% | 3676 |
|
|
2017
Q4 | $73K | Buy |
+795
| New | +$89.6K | ﹤0.01% | 3622 |
|
|
2016
Q2 | – | Sell |
-1,806
| Closed | -$163K | – | 3756 |
|
|
2016
Q1 | $163K | Buy |
+1,806
| New | +$160K | ﹤0.01% | 3507 |
|
Other funds holding IMDX
BC
AIC
PVI
VCM
HCM
FIA
VFT
State Street's IMDX Position: Q1 2026 in Review
State Street increased its Insight Molecular Diagnostics (IMDX) stake by 6.3% in Q1 2026, buying an estimated $17.4K and bringing the position to 50,754 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #3936.
State Street first reported a position in IMDX in Q1 2016 and has held it in 31 quarters since. The position peaked at $7.25M in Q2 2021. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.
- State Street held 50,754 shares of Insight Molecular Diagnostics worth $166K as of Q1 2026.
- State Street bought 3,000 Insight Molecular Diagnostics shares in Q1 2026, an estimated $17.4K.
- Insight Molecular Diagnostics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3936 holding.
- State Street first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 31 quarters since.
- State Street's Insight Molecular Diagnostics position peaked at $7.25M in Q2 2021.
- 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.